Support for abiraterone plus ADT plus docetaxel in metastatic prostate cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 19 / Springer Healthcare

Support for abiraterone plus ADT plus docetaxel in metastatic prostate cancer

Oncology Prostate Cancer ESMO-2021

Description

Robert Huddart gives his view of the PEACE-1 findings looking at a triplet of abiraterone, androgen deprivation therapy and docetaxel for metastatic castration-sensitive prostate cancer.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.